Quinolines and derivatives
Apexbio Technology LLC CCG-1423 285986-88-1 200mg
CCG-1423 (CAS 285986-88-1) is a small molecule inhibitor targeting RhoA transcriptional signaling pathways It disrupts the interaction between myocardin-related transcription factor A (MRTF-A) and importin / 1 while not affecting the binding of monomeric G-actin to MRTF-A CCG-1423 exhibits selective nanomolar to low micromolar potency against cells with Rho pathway overexpression leading to inhibition of DNA synthesis cellular proliferation and invasion In highly metastatic melanoma cells with elevated RhoC it enhances caspase-3 activation indicating a role in apoptosis modulation CCG-1423 serves as a valuable tool for investigating Rho GTPase-mediated processes in cancer and related pathologies
Apexbio Technology LLC Regorafenib monohydrate 1019206-88-2 200mg
Regorafenib monohydrate (CAS 1019206-88-2) is a multitargeted tyrosine kinase inhibitor that suppresses numerous intracellular and membrane receptor tyrosine kinases (RTKs) including VEGFR (types 1-3) PDGFR- FGFR-1 RET TIE2 c-KIT Raf-1 and BRAF (wild-type and V600E mutant) It inhibits angiogenic RTKs such as VEGFR-2 with IC50 values ranging from approximately 4 2 to 46 nM and oncogenic RTKs like c-KIT and RET with IC50 values around 1 5 to 28 nM Regorafenib demonstrates antiproliferative activity in vitro (mean IC50 1 M) and reduces tumor progression in xenograft animal models supporting its use in cancer research involving breast colorectal thyroid pancreatic cancers melanoma and gastrointestinal stromal tumors